Posted by Michael Wonder on 14 Sep 2022
PHARMAC announces medicines bundle to provide more treatment options for New Zealanders
14 September 2022 - PHARMAC is considering funding two medicines as part of a new bundle agreement that would offer new treatment options for people experiencing schizophrenia and for people with one type of blood cancer.
In the consultation issued today, PHARMAC is seeking feedback on proposals to fund:
- Paliperidone three-monthly (Invega Trinza) for people with schizophrenia
- Ibrutinib (Imbruvica) for people with relapsed/refractory chronic lymphocytic leukaemia following treatment with venetoclax
